Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and fewer side effects. Nevertheless, despite some successes drug development remains painfully slow. Here, the issues involved and suggest ways in which this process can be improved and expedited. Shift for integrated cancer research and biomarker-driven adaptive, hypothesis testing for clinical trials. The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi